FIELD: medicine, pharmaceutics.
SUBSTANCE: this invention relates to cocrystalline form of (1S)-1,5-anhydro-1-[3-(1-benzothiene-2-ylmethyl)-4-fluorophenyl]-D-glucitol (compound A) with L-proline. Proposed cocrystalline form is a promising anti-diabetes medicine.
EFFECT: cocrystalline form of compound is characterised with constant composition, improved stability in storage, and also low hygroscopicity, and is suitable for use as crystalline medicinal substance to produce pharmaceutical preparations.
11 cl, 1 ex, 2 tbl, 10 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| C-GLYCOSIDE DERIVATIVES AND THEIR SALTS | 2004 |
|
RU2317288C2 |
| AZULENE DERIVATIVE, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHOD FOR TREATMENT OF DIABETES MELLITUS | 2003 |
|
RU2295522C2 |
| AMIDE COMPOUNDS | 2015 |
|
RU2684906C2 |
| AMINE SOLVATE OF SODIUM GLUCOSE OPENER OF SODIUM GLUCOSE OPENER AND METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2017 |
|
RU2710230C1 |
| C-PHENYL GLYCITOL COMPOUND FOR TREATING DIABETES | 2007 |
|
RU2437876C2 |
| NOVEL CRYSTALLINE FORMS OF DIPEPTIDYLPEPTIDASE-IV INHIBITORS | 2012 |
|
RU2598072C2 |
| COCRYSTALLINE FORM OF NIFLUMIC ACID WITH ISONICOTINAMIDE OT CAFFEINE | 2013 |
|
RU2536484C1 |
| DIFLUNISAL CO-CRYSTALLINE FORM | 2016 |
|
RU2617849C1 |
| CRYSTALLINE FORMS OF THE DIHYDROPYRIMIDIN DERIVATIVES | 2013 |
|
RU2646599C2 |
| CO-CRYSTALLINE FORM OF BICALUTAMIDE | 2012 |
|
RU2510392C1 |
